Actelion Share Price CBOE

Stocks

End-of-day quote CBOE
- ^CHF	-

31/07/17	Actelion : France's Sanofi raises earnings forecast, pleased with eczema drug uptake	RE
18/07/17	Johnson & Johnson : J&J sees sales growth in near-term; raises 2017 profit forecast	RE

31/07/17	Actelion : France's Sanofi raises earnings forecast, pleased with eczema drug uptake	RE
18/07/17	Johnson & Johnson : J&J sees sales growth in near-term; raises 2017 profit forecast	RE
18/07/17	Johnson & Johnson : J&J sees sales growth in near-term; raises 2017 profit forecast	RE
09/06/17	Actelion : Johnson & Johnson expects to complete Actelion purchase on June 16	RE
09/06/17	Actelion : Johnson & Johnson expects to complete Actelion purchase on June 16	RE
09/06/17	Actelion : Johnson & Johnson expects to complete of Actelion offer on June 16	RE
22/05/17	Akzo Nobel : Cross-border M&A between U.S. and European firms at 10 year high	RE
18/05/17	Actelion : Johnson & Johnson offers EU concessions over Actelion deal	RE
20/04/17	Actelion : Johnson & Johnson target Actelion could exit Swiss benchmark SMI index this month	RE
18/04/17	Actelion : Johnson & Johnson first quarter revenue misses estimates; new forecast includes Actelion	RE
05/04/17	Actelion : shareholders back R&D spinoff, keep J&J deal on track	RE
31/03/17	Actelion : J&J declares Actelion tender offer a success, sees closing in second quarter	RE
22/02/17	Genmab A/S : and J&J's cancer drug set for blockbuster sales this year	RE

06/04/20	Actelion : Pharmaceuticals US, Inc, - Results from Expert Delphi Consensus Survey on Treatment of Pulmonary Arterial Hypertension with Oral Prostacyclin Pathway Agents	AQ
31/10/17	Actelion : Cancellation of publicly held Actelion shares and delisting from SIX Swiss Exchange as of November 7, 2017	GL
30/06/17	Actelion : Befreiung von Publizitätspflichten zur Aufrechterhaltung der Kotierung	GL
16/06/17	Actelion : Johnson & Johnson Completes Acquisition of Actelion	GL
15/06/17	Actelion : Publication of Idorsia's prospectus relating to the listing of Idorsia Ltd on SIX Swiss Exchange	PU

29/01/18	Après Bioverativ, Sanofi s'empare de la biotech belge Ablynx pour 3,9 mrd EUR
29/01/18	Après Bioverativ, Sanofi rachète la biotech belge Ablynx pour 3,9 mrd EUR
22/01/18	Avec Bioverativ, Sanofi devient un leader mondial dans l'hémophilie
31/10/17	Actelion : Cancellation of publicly held Actelion shares and delisting from SIX Swiss Exchange as of November 7, 2017
30/10/17	Actelion: la décotation est agendée au 7 novembre

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
WUXI APPTEC CO., LTD.	-1.59%	-3.35%	+52.37%	+91.62%	69.54B
ARGENX SE	-2.48%	+1.09%	+44.21%	+87.95%	64.97B
WUXI BIOLOGICS (CAYMAN) INC.	-3.57%	+0.49%	+35.74%	+10.62%	26.51B
INSMED INCORPORATED	-2.35%	-5.75%	-12.90%	+436.87%	25.89B
BIONTECH SE	-8.37%	-12.43%	+2.08%	-18.39%	25.64B
PHARMAESSENTIA CORPORATION	-0.96%	+10.36%	+283.06%	+429.04%	20.22B
GENMAB A/S	-1.51%	+0.47%	+29.35%	-19.62%	19.98B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	-3.36%	-4.93%	+2.30%	+549.93%	15.69B
EXELIXIS, INC.	-1.47%	+0.68%	+45.51%	+142.00%	13.49B
Average	-2.84%	-1.93%	+53.52%	+190.00%	31.33B
Weighted average by Cap.	-2.69%	-1.50%	+50.16%	+149.08%

Employees

Sector